Form 4: Rocket Pharma Officer Sells Shares for Tax

Rocket Pharmaceuticals' Chief Medical Officer, Jonathan David Schwartz, sold shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Jonathan David Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, Inc. (RCKT), reported sales of common stock.
• On August 18, 2025, 1,680 shares were sold at $3.065 per share.
• On August 19, 2025, an additional 805 shares were sold at $2.996 per share.
• These sales were executed to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following these transactions, beneficial ownership stands at 221,609 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine sale of shares by an officer to cover tax obligations associated with RSU vesting, which is a common and non-discretionary event, thus having a neutral impact on sentiment.

Positives

• The sales were for tax withholding obligations, indicating a non-discretionary transaction rather than a sale driven by a lack of confidence in the company.

Negatives

• A reduction in the direct beneficial ownership of common stock by a key officer, although for a specific, non-discretionary reason.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it pertains solely to an insider's stock transactions.

Management Comments

• The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Industry Context

This type of transaction (sale to cover taxes on RSU vesting) is a standard practice across industries for executives receiving equity compensation. It does not reflect specific industry trends or competitive dynamics.

Stakeholder Impact

• Minimal impact on shareholders, as the sale is a routine, non-discretionary transaction for tax purposes and does not indicate a change in company fundamentals or officer confidence.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by an officer to cover tax obligations from RSU vesting. This type of transaction is common and does not reflect a change in the company's fundamentals or the officer's confidence, thus it does not warrant a change in investment recommendation.

Keywords

Rocket Pharmaceuticals, RCKT, Form 4, insider trading, stock sale, RSU, executive compensation, Jonathan David Schwartz